<DOC>
	<DOCNO>NCT00947466</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics tolerability buprenorphine patch child require opioid pain relief moderate severe mouth pain .</brief_summary>
	<brief_title>A Study Characterize Pharmacokinetics Tolerability Buprenorphine Patches Children With Moderate Severe Mouth Pain</brief_title>
	<detailed_description>Subjects screen eligibility eligible apply buprenorphine patch ( Day 1 ) . The patch wear 7 day time , safety assessment , pain score , mucositis score , PK sample &amp; vital sign assess day . After patch removal subject continue assessment daily basis Day 12 . The subject follow 10 day ( Day 22 ) collect information ongoing/new SAEs/AEs .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female child experience severe mouth pain secondary chemotherapy induce mucositis require opioid analgesic therapy inpatient , minimum Day 8 ( patch removal ) . 2 . Subjects experience 'severe ' pain Investigators clinical judgment . 3 . Body weight ≥ 15 kg . Subjects weigh ≥ 25 kg recruit first phase study weigh &lt; 25 kg also include second phase , ( successful review IDSMC ) . Upper age range 16 year . 4 . In dwell IV cannula central line blood obtain . 5 . Written inform consent obtain parent ( ) /legal representative , possible assent obtain subject appropriate , line local regulation . 6 . Females child bear potential must negative urine pregnancy test Principal Investigator consider reasonable possibility pregnancy . Exclusion criterion : 1 . Subjects know hypersensitivity buprenorphine excipients transdermal system , outline Summary Product Characteristics BuTrans . 2 . Known hypersensitivity opioids . 3 . Skin disease affect application local tolerance BTDS . 4 . Clinically significant history allergic reaction wound dressing adhesive . 5 . Severe respiratory impairment . 6 . Clinically significant hepatic dysfunction . 7 . Severe renal impairment . 8 . Subjects receive MAO inhibitor take within previous 2 week . 9 . Subjects receive hypnotic central nervous system ( CNS ) depressant , investigator 's opinion , may pose risk additional CNS depression study medication . 10 . Subjects take buprenorphine preparation last 14 day . 11 . Subjects myasthenia gravis . 12 . Subjects convulsive disorder , head injury , shock , reduce level consciousness uncertain origin . 13 . Subjects currently participate another clinical research study involve new chemical entity ( NCE ) unless sole purpose trial time BUP1501 screen long term followup/survival data subject participate clinical study within previous 30 day . Participation chemotherapy clinical trial evaluate NCE accept inclusion . 14 . Subjects pregnant , lactate Investigators opinion risk conceive . 15 . Previous enrollment clinical study . 16 . Subjects Investigator believe unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Buprenorphine transdermal patch ( BTDS )</keyword>
	<keyword>Moderate severe mouth pain</keyword>
	<keyword>Chemotherapy induce mucositis</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>